Redefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships BEVERLY, Mass.–(BUSINESS WIRE)–#FreudenbergRedefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships BEVERLY, Mass.–(BUSINESS WIRE)–#Freudenberg

Freudenberg Medical Ushers in a New Era for Hydrophilic Coatings with Launch of LUBRITEQ™

5 min read

Redefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships

BEVERLY, Mass.–(BUSINESS WIRE)–#Freudenberg—Freudenberg Medical, a global contract design and manufacturing (CDMO) partner to the medical device and biopharma industry, today announced the launch of LUBRITEQ™, a new high-performance hydrophilic coating solution, along with a comprehensive suite of associated development and manufacturing services. LUBRITEQ™ is now available globally across Freudenberg Medical’s vertically integrated operations.

With the launch of LUBRITEQ™, Freudenberg Medical becomes the only hydrophilic coating provider to unite advanced surface chemistry with deep, in-house medical device design and manufacturing capabilities—bringing together complementary technologies to enhance manufacturability and deliver greater productivity and reliability across the entire product development lifecycle.

“Hydrophilic coatings and device design must work in perfect harmony to deliver optimal performance, yet the industry has traditionally approached them as separate disciplines,” said Michael McGee, CEO of Freudenberg Medical. “As a uniquely integrated technical partner, we enable customers to move faster, with less risk and greater confidence, by combining product design, advanced materials, precision coatings, and application expertise for seamless development, scale-up, and launch.”

Built on a Deep Expertise in Surface Chemistry

Freudenberg Medical brings more than 25 years of experience in coating science, supported by a proven legacy of innovation, including expertise integrated through Hemoteq, that has enabled customers to achieve multiple industry firsts in complex drug-device and surface modification solutions.

“With more than 40 coating scientists, chemical engineers and technicians working alongside 250 medical device & catheter engineers globally, we have unparalleled expertise in developing complex chemistry and drug-device solutions for our customers,” said McGee. “We already support over one million medical devices each year for functional surface coatings, making the introduction of LUBRITEQ™, our hydrophilic coating solution, a natural evolution and logical next step aligned with our customers’ needs.”

Shaped by Customer Needs

Freudenberg Medical’s decision to enter the hydrophilic coatings market was guided by extensive engagement with customers and industry stakeholders to understand where existing solutions and partnerships can be improved, and where unmet needs continue to exist. Through these exchanges, it became clear that while coating technologies have advanced, customer needs are not being fully served—particularly when it comes to the flexibility of support services and complexities of royalties, licenses and fees.

“We heard consistent feedback that directly shaped our strategy,” said Freudenberg Medical’s Chief Commercial Officer, Keith Kiernan. “Customers aren’t just looking for a better coating—they’re looking for a better partner to de-risk their product launches. We deliberately set out to deliver a solution—and a partnership model—that reflects exactly what customers told us they need. No royalties, no rigidity—just coating performance, partnership and progress.”

Introducing LUBRITEQ™ Hydrophilic Coating & Services

LUBRITEQ™ is an advanced, UV-curable, single-step hydrophilic coating engineered for versatility and performance across a wide range of medical device applications and polymer & metal substrates. The coating delivers high lubricity with exceptional durability, consistent uniformity and ultra-low particulates. LUBRITEQ™ is customizable to optimize performance for specific device requirements and is compatible with virtually all approved materials used in medical device designs.

Recognizing that coating performance alone is not enough, Freudenberg Medical is launching LUBRITEQ™ alongside a comprehensive services model that supports customers across the full product lifecycle—from early feasibility through commercial production. Services include a rapid two-week first feasibility turnaround, tailored coating customization programs, and flexible volume-manufacturing options, including process transfer to the customer or contract coating support across Freudenberg Medical’s global site network. This integrated approach eliminates hand-offs across multiple suppliers, reducing risk and accelerating product development timelines.

Customer-First and Transparent, Commercial Model

In contrast to traditional industry practices, Freudenberg Medical is introducing a straightforward and transparent commercial model for LUBRITEQ™, designed to eliminate hidden costs and reduce program launch risk. Customers can access a high-performance hydrophilic coating solution with no royalties, no fixed or annual fees, and no regulatory file access fees.

Together, these elements remove commercial barriers and enable long-term, trust-based partnerships.

“With LUBRITEQ™, Freudenberg Medical is raising the bar for what a hydrophilic coating partner can and should be,” said CEO Michael McGee. “The early responses we’re seeing from customers confirm that we’re meeting a real need. Great technology, great service and a commercial model built on trust—that’s the standard we are setting.”

Freudenberg Medical is launching LUBRITEQ™ at MD&M West. Visit Booth 2609 to learn more about LUBRITEQ™ and discover how Freudenberg Medical is redefining what’s possible in hydrophilic coatings. Visit LUBRITEQ™ for more information.

About Freudenberg Medical

Freudenberg Medical is a trusted strategic CDMO partner to medical device and pharmaceutical companies, committed to delivering high-quality solutions from ideation to market launch and volume production. With over 2,900 associates across 12 global manufacturing sites in key MedTech hubs and proven expertise in materials and technologies, Freudenberg Medical offers an extensive range of vertically integrated capabilities: from minimally invasive solutions including complex catheters, hypotubes, steerable shafts, handles as well as drug and hydrophilic coatings to precision molding, two-shot and micro molding, advanced extrusions, and solutions for smart medical devices. www.freudenbergmedical.com

Contacts

Media Contacts
Laura Kirstein
Director Marketing and Communications
Freudenberg Medical
laura.kirstein@freudenbergmedical.com

Maura Leahy
Strategic Marketing
Freudenberg Medical
maura.leahy@freudenbergmedical.com

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Verimatrix: Sale of Extended Threat Defense Assets (Mobile Application Protection) to Guardsquare

Verimatrix: Sale of Extended Threat Defense Assets (Mobile Application Protection) to Guardsquare

Completion of the sale of XTD assets (code and mobile application protection), including a portfolio of patents and a team of experts. The Group is refocusing on
Share
AI Journal2026/02/06 00:49
IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

The post IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge! appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 18:00 Discover why BlockDAG’s upcoming Awakening Testnet launch makes it the best crypto to buy today as Story (IP) price jumps to $11.75 and Hyperliquid hits new highs. Recent crypto market numbers show strength but also some limits. The Story (IP) price jump has been sharp, fueled by big buybacks and speculation, yet critics point out that revenue still lags far behind its valuation. The Hyperliquid (HYPE) price looks solid around the mid-$50s after a new all-time high, but questions remain about sustainability once the hype around USDH proposals cools down. So the obvious question is: why chase coins that are either stretched thin or at risk of retracing when you could back a network that’s already proving itself on the ground? That’s where BlockDAG comes in. While other chains are stuck dealing with validator congestion or outages, BlockDAG’s upcoming Awakening Testnet will be stress-testing its EVM-compatible smart chain with real miners before listing. For anyone looking for the best crypto coin to buy, the choice between waiting on fixes or joining live progress feels like an easy one. BlockDAG: Smart Chain Running Before Launch Ethereum continues to wrestle with gas congestion, and Solana is still known for network freezes, yet BlockDAG is already showing a different picture. Its upcoming Awakening Testnet, set to launch on September 25, isn’t just a demo; it’s a live rollout where the chain’s base protocols are being stress-tested with miners connected globally. EVM compatibility is active, account abstraction is built in, and tools like updated vesting contracts and Stratum integration are already functional. Instead of waiting for fixes like other networks, BlockDAG is proving its infrastructure in real time. What makes this even more important is that the technology is operational before the coin even hits exchanges. That…
Share
BitcoinEthereumNews2025/09/18 00:32
BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44